"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
    
			
			
				
				
					
						| Descriptor ID | D020522 | 
					
						| MeSH Number(s) | C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525 | 
					
						| Concept/Terms | Lymphoma, Mantle-CellLymphoma, Mantle-CellLymphoma, Mantle CellLymphomas, Mantle-CellMantle-Cell LymphomasLymphocytic Lymphoma, Diffuse, Poorly DifferentiatedLymphocytic Lymphoma, Diffuse, Poorly-DifferentiatedMantle-Zone LymphomaLymphoma, Mantle-ZoneLymphomas, Mantle-ZoneMantle Zone LymphomaMantle-Zone LymphomasLymphoma, Lymphocytic, Diffuse, Intermediate DifferentiatedLymphoma, Lymphocytic, Diffuse, Poorly-DifferentiatedLymphoma, Small-Cell, CentrocyticMantle-Cell LymphomaMantle Cell LymphomaDiffuse Lymphocytic Lymphoma, Poorly-DifferentiatedDiffuse Lymphocytic Lymphoma, Poorly DifferentiatedLymphoma, Centrocytic Small-CellCentrocytic Small-Cell LymphomaCentrocytic Small-Cell LymphomasLymphoma, Centrocytic Small CellLymphomas, Centrocytic Small-CellSmall-Cell Lymphoma, CentrocyticSmall-Cell Lymphomas, Centrocytic
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2004 | 0 | 1 | 1 | 
| 2006 | 1 | 0 | 1 | 
| 2009 | 2 | 0 | 2 | 
| 2010 | 1 | 1 | 2 | 
| 2011 | 1 | 1 | 2 | 
| 2012 | 1 | 0 | 1 | 
| 2013 | 3 | 0 | 3 | 
| 2015 | 2 | 0 | 2 | 
| 2016 | 1 | 0 | 1 | 
| 2017 | 1 | 1 | 2 | 
| 2018 | 2 | 0 | 2 | 
| 2019 | 0 | 1 | 1 | 
| 2020 | 3 | 0 | 3 | 
| 2021 | 4 | 0 | 4 | 
| 2023 | 2 | 0 | 2 | 
| 2024 | 1 | 0 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.
						
					
								- 
								CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531. 
- 
								A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993. 
- 
								Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec; 23(7):773-787. 
- 
								Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 12; 195(5):757-763. 
- 
								Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 11; 27(11):911.e1-911.e7. 
- 
								Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. Am J Surg Pathol. 2021 07 01; 45(7):939-944. 
- 
								Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv. 2021 01 12; 5(1):185-197. 
- 
								An update on options of therapy for aggressive mantle cell lymphoma. Leuk Lymphoma. 2020 09; 61(9):2036-2049. 
- 
								Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494. 
- 
								Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593.